PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics CEO’s 10‑b‑5‑1 trades reveal confidence: buying low, selling high as shares hit $151.88, balancing liquidity with long‑term stake.

Protagonist Therapeutics insider Waddill William D. showcases a disciplined buy‑sell‑exercise strategy, revealing confidence in the company’s 2026 biotech upside and guiding investors on potential growth.

Protagonist Therapeutics insider buys reveal confidence in its peptide pipeline, boosting liquidity and positioning for stronger market access.

Protagonist Therapeutics insider Waddill buys shares at a 5 % discount, signaling confidence in upcoming IND/Phase 2 milestones and potential upside for investors.

CEO insider trades at Protagonist Therapeutics reveal confidence in peptide pipeline, Phase‑III success, and regulatory progress—key for investors.

Protagonist Therapeutics insider trades reveal routine liquidity moves, not strategic bets – investors can focus on the company’s promising peptide pipeline and market‑high price potential.

Protagonist Therapeutics insider trading sparks investor curiosity, yet breakthrough Phase IIa results for PT‑301 show promising efficacy and safety for rheumatoid arthritis.

CEO Dinesh Patel’s recent 50k‑share sale at $104.38 shows Protagonist Therapeutics’ insider timing strategy amid a 7.5% weekly gain, revealing insights on exec confidence and market‑impact rules in biotech.

Insider buying at Protagonist Therapeutics signals confidence—executive purchases at $10.84 hint at undervaluation and potential upside, especially with upcoming Phase II trials.